Luvastab- 40
A Highly Attractive Option For ASCVD

Composition : Fluvastatin 40mg

Form : Tablets / Pack : 1 X 10's / Type : AA

Description : One‐hundred and forty‐five trials (36 placebo controlled and 109 before and after) evaluated the dose‐related efficacy of fluvastatin in 18,846 participants. The participants were of any age with and without evidence of cardiovascular disease, and fluvastatin effects were studied within a treatment period of three to 12 weeks. Log dose‐response data over doses of 2.5 mg to 80 mg revealed strong linear dose‐related effects on blood total cholesterol and LDL cholesterol and a weak linear dose‐related effect on blood triglycerides. There was no dose‐related effect of fluvastatin on blood HDL cholesterol. Fluvastatin 10 mg/day to 80 mg/day reduced LDL cholesterol by 15% to 33%, total cholesterol by 11% to 25% and triglycerides by 3% to 17.5%. For every two‐fold dose increase there was a 6.0% (95% CI 5.4 to 6.6) decrease in blood LDL cholesterol, a 4.2% (95% CI 3.7 to 4.8) decrease in blood total cholesterol and a 4.2% (95% CI 2.0 to 6.3) decrease in blood triglycerides. The quality of evidence for these effects was judged to be high - Cochrane Database of Systematic Reviews - Published : 06 March 2018

View more products with following salts

Cylnida- BS
Dual Approach Anti-Hypertensive

Composition : Bisoprolol 5mg + Cilnidipine 10mg

Form : Tablets / Pack : 1 X 10's / Type : AA

Description : Since Cilnidipine inhibits N-type channels thus it inhibits the activation of the sympathetic nervous system hence preferred drug for White Coat Hypertension and morning hypertension (closely associated with sympathetic activity) Cilnidipine has been extensively studied by researchers in its preclinical and clinical development phases. Renoprotective, neuroprotective and cardioprotective effects of Cilnidipine have been demonstrated in clinical practice - Indian Heart J. 2013 Dec; 65(6): 691–695. Bisoprolol is a beta-blocker with high selectivity for beta-1 ARs. It has no intrinsic sympathomimetic activity and no membrane stabilizing activity. Lacking of any ancillary property, it may probably be considered as “the purest” beta-1 AR blocker for the treatment of HF- Ther Clin Risk Manag. 2007 Aug; 3(4): 569–578.

View more products with following salts

Atorts-40
Assured Lipid Management Regimen

Composition : Atorvastatin 40mg

Form : Tablets / Pack : 1 X 10's / Type : AA

Description : Atorvastatin is an appropriate first-line lipid-lowering therapy in numerous groups of patients at low to high risk of CHD. Additionally it has a definite role in treating patients requiring greater decreases in LDL-cholesterol levels. Long-term studies are under way to determine whether achieving very low LDL-cholesterol levels with atorvastatin is likely to show additional benefits on morbidity and mortality in patients with CHD - Drugs. 2001;61(12):1835-81.

View more products with following salts

Atorts-20
Assured Lipid Management Regimen

Composition : Atorvastatin 20mg

Form : Tablets / Pack : 1 X 10's / Type : AA

Description : Atorvastatin is an appropriate first-line lipid-lowering therapy in numerous groups of patients at low to high risk of CHD. Additionally it has a definite role in treating patients requiring greater decreases in LDL-cholesterol levels. Long-term studies are under way to determine whether achieving very low LDL-cholesterol levels with atorvastatin is likely to show additional benefits on morbidity and mortality in patients with CHD - Drugs. 2001;61(12):1835-81.

View more products with following salts

Atorts-10
Assured Lipid Management Regimen

Composition : Atorvastatin 10mg

Form : Tablets / Pack : 1 X 10's / Type : AA

Description : Atorvastatin is an appropriate first-line lipid-lowering therapy in numerous groups of patients at low to high risk of CHD. Additionally it has a definite role in treating patients requiring greater decreases in LDL-cholesterol levels. Long-term studies are under way to determine whether achieving very low LDL-cholesterol levels with atorvastatin is likely to show additional benefits on morbidity and mortality in patients with CHD - Drugs. 2001;61(12):1835-81.

View more products with following salts

Ranhox-500
New Avenue For Angina Management

Composition : Ranolazine 500mg Extended Release

Form : Tablets / Pack : 1 X 10's / Type : AA

Description : The clinical efficacy, safety and tolerability of Ranolazine have been established in large clinical trials. Subgroup analyses have shown that patients with chronic angina appear to derive significant clinical and symptomatic benefit from ranolazine and possibly reductions in ischemia. Ranolazine appears to have other promising nonanginal effects, including glycemic control, improvements in endothelial function and decreases in the incidence of atrial fibrillation and other arrhythmias.Less than 2% of patients experience common side effects, the symptoms are mild, and they occur within the 1st few weeks of therapy - Texas Heart Institute Journal- 2010; 37(6): 641–647.

View more products with following salts